In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy Officer at Clinical Outcome Solutions, to discuss whether the field of clinical outcome assessment has started sacrificing “good for perfect.” Together, they explore the role of regulatory guidance and clinical development timelines, specifically the role of measurement science in already tight development timelines, when to modify a legacy instrument versus build something new, and why getting measurement scientists involved early is the key to a successful COA strategy.
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Lina Eliasson PhD CPsycho, Founding Partner...
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences sits down with Dr. Elizabeth Bacci, Senior Research Scientist...
Artificial intelligence is redefining what’s possible across the clinical development lifecycle, but with rapid innovation comes the need for thoughtful oversight. In this episode...
